STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 102 filers reported holding STOKE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,977 | -84.5% | 81,720 | -58.2% | 0.00% | – |
| Q2 2023 | $2,076,017 | +4.7% | 195,298 | -17.9% | 0.00% | – |
| Q1 2023 | $1,982,249 | -34.7% | 237,965 | -27.7% | 0.00% | -100.0% |
| Q4 2022 | $3,037,649 | -12.9% | 329,106 | +21.1% | 0.00% | 0.0% |
| Q3 2022 | $3,489,000 | +110.9% | 271,781 | +117.0% | 0.00% | – |
| Q2 2022 | $1,654,000 | -38.9% | 125,237 | -2.6% | 0.00% | -100.0% |
| Q1 2022 | $2,706,000 | +1239.6% | 128,532 | +1426.1% | 0.00% | – |
| Q4 2021 | $202,000 | -81.3% | 8,422 | -80.2% | 0.00% | – |
| Q3 2021 | $1,083,000 | -63.1% | 42,567 | -51.2% | 0.00% | – |
| Q2 2021 | $2,936,000 | +68.5% | 87,232 | +94.6% | 0.00% | – |
| Q1 2021 | $1,742,000 | +45.0% | 44,830 | +131.1% | 0.00% | – |
| Q4 2020 | $1,201,000 | +149.2% | 19,400 | +34.7% | 0.00% | – |
| Q3 2020 | $482,000 | +11.6% | 14,400 | -23.7% | 0.00% | – |
| Q1 2020 | $432,000 | +45.9% | 18,865 | +80.3% | 0.00% | – |
| Q4 2019 | $296,000 | -89.8% | 10,465 | -89.5% | 0.00% | -100.0% |
| Q2 2019 | $2,911,000 | – | 99,818 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |